Neuro Advance Boston promises to be an energetic, innovative environment for cross-talk among leaders in the neuro research and investment communities,” says Betsy Nabel, President of Brigham & Women’s, “encouraging faster progress from lab to market.
Boston, MA (PRWEB) September 01, 2015
Leading CEOs, CSOs, CMOs, and heads of neuro from top biopharmaceutical companies in the neuro and pain management space join prominent academics and key investors for Neuro Advance Boston, October 14, 2015 at the Joseph B. Martin Conference Center at Harvard Medical School in Boston.
Neuro Advance Boston focuses on the latest developments and opportunities in neuroscience for creating new therapies. The agenda features luminaries in neuroscience research and development, as well as executives of the next generation of the leading neuro companies, who will explore the most relevant issues facing neuroscience and biotechnology today. Panel topics include gene therapy approaches to CNS disorder, Alzheimer’s trends and predictions, new horizons in stem cell therapy, advances in psychiatry, chemical neuro stimulation, and more.
"Neuro Advance Boston promises to be an energetic, innovative environment for cross-talk among leaders in the neuro research and investment communities,” says Betsy Nabel, President of Brigham and Women’s Hospital, “encouraging faster progress from lab to market."
Steve Paul, CEO of Voyager Therapeutics, Venture Partner of Third Rock Ventures, and the Former President of the Lilly Research Laboratories, adds: “Neuro Advance Boston brings together an absolutely stellar group of scientists, clinical investigators, entrepreneurs and investors in a completely unrehearsed forum for a candid and very enlightening discussion of the exciting and rapidly maturing field of neuroscience and the many opportunities this science affords for creating innovative new treatments for many of humankind’s most devastating afflictions."
Additional conference speakers include: Sunil Agarwal (Ultragenyx), Jörn Aldag (uniQure), Samantha Budd Haeberlein (Biogen), Wayne Drevets (Janssen), Peter Lansbury (Lysosomal Therapeutics), Tom Large (Sunovion), Remy Luthringer (Minerva), Art Pappas (Pappas Ventures), Darryle Schoepp (Merck), Amir Tamiz (NIH), Akshay Vaishnaw (Alnylam), Tom Wessel (Flex Pharma), and other prominent industry leaders.
For more information or to register for the conference, visit: http://bit.ly/1AAuZIj
ABOUT THE BOSTON BIOTECH CONFERENCES
The Boston Biotech Conferences (BBC)’s mission is to build a vibrant community of biopharma leaders, which will help to drive biopharma innovation in biotech, by convening leaders across industry and academia. The conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking, and corporate development within the biopharma community.
The meetings are invitation-only, off-the-record forums that bring together the past, present, and future leaders in the healthcare community to network, exchange ideas and share insights into the industry's challenges and opportunities. For more information or to register, visit http://www.bbbiotechconference.com.